Halozyme Therapeutics Inc

Open

SectorGezondheidszorg

77 -1.66

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

75.55

Max

78.51

Belangrijke statistieken

By Trading Economics

Inkomsten

292M

150M

Verkoop

-75M

377M

K/W

Sectorgemiddelde

26.302

56.269

EPS

1.221

Winstmarge

39.832

Werknemers

423

EBITDA

-62M

220M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+4.95% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.2B

8.9B

Vorige openingsprijs

78.66

Vorige sluitingsprijs

77

Nieuwssentiment

By Acuity

50%

50%

123 / 342 Rangschikking in Healthcare

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jun 2026, 23:36 UTC

News
Social Media

MercadoLibre Inc. shares declined in after-market trading following news of a securities fraud investigation related to loan term disclosures, raising investor concerns.

30 jun 2026, 23:36 UTC

News
Correlated Moves
Macro News
ETF Constituents

Vanguard Information Technology ETF's performance has been roughly flat during after-market hours, following a positive environment for technology stocks and the Nasdaq's rebound.

30 jun 2026, 23:26 UTC

News
Correlated Moves

iShares iBoxx $ Investment Grade Corporate Bond ETF trades lower in after-market hours, amid a broader decline in U.S. equity indices and technology stocks.

30 jun 2026, 23:21 UTC

News
Social Media

Micron Technology shares rose after hours, buoyed by a $250 million investment and significant revenue growth linked to AI chipmakers.

30 jun 2026, 23:11 UTC

News

Comcast Corp shares rose in after-market trading, continuing an upward trend. The company's market cap now exceeds that of American Tower, ranking 135th in the S&P 500.

30 jun 2026, 23:06 UTC

News
Correlated Moves

The US 10Y Treasury Bond Index is near unchanged in after-market hours, following a slight increase earlier in the day. The iShares 7-10 Year Treasury Bond ETF mirrors this stability.

30 jun 2026, 23:06 UTC

Social Media
News

Microsoft shares rise in after-market hours, driven by strength in the Systems Software sub-sector and a new partnership with Chevron for a natural gas facility.

30 jun 2026, 23:02 UTC

Social Media
News

Tesla Inc. shares are lower in after-market hours following Michael Burry's short position disclosure and a fatal incident involving one of its vehicles.

30 jun 2026, 23:02 UTC

News

The iShares 20+ Year Treasury Bond ETF is lower in after-market trading, reflecting broader declines in U.S. indices and mixed market conditions.

30 jun 2026, 23:02 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, driven by losses in top holdings NVIDIA, Tesla, and Meta, despite slight gains in the Nasdaq 100 Index.

30 jun 2026, 23:01 UTC

News

Fox Corp has secured a $1 billion loan to fund its Roku acquisition. Shares are higher in after-market hours, aided by a strong Broadcasting sector.

30 jun 2026, 22:51 UTC

News

Vanguard Total Bond Market ETF is lower in after-market hours, reflecting broader market pullbacks amid geopolitical tensions and fluctuating oil prices.

30 jun 2026, 20:08 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline. Sharplink's acquisition of 10,000 ETH at $1,611 has not prevented the drop.

30 jun 2026, 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

30 jun 2026, 20:07 UTC

Social Media
News

Intel Corp shares are advancing, driven by bullish semiconductor activity and increased buying interest. The stock reached a post-alert high of $131.14.

30 jun 2026, 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA shares rose following SemiAnalysis's bullish projection for data center revenue, expected to exceed consensus by 20% in fiscal 2027's second half.

30 jun 2026, 20:07 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline and broader market pressures. Earlier, it dipped to a session low of $1,611.

30 jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher after the Supreme Court agreed to hear its appeal in the Epic Games antitrust case, potentially benefiting App Store fees.

30 jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Analyst raises AMD price target to $615, citing strong AI demand. Shares are trading higher since Monday, reflecting positive market sentiment.

30 jun 2026, 20:03 UTC

Social Media
Correlated Moves
ETF Constituents
News

Invesco QQQ Trust Series I advances today, driven by positive technology sector sentiment and strong performance from major contributors like AMD and Apple.

30 jun 2026, 20:03 UTC

News
ETF Constituents

Health Care Select Sector SPDR Fund declines as health care underperforms, with Eli Lilly and Stryker contributing to the negative performance during Tuesday's session.

30 jun 2026, 20:03 UTC

Correlated Moves
News
ETF Constituents

Germany's retail sales rose 1.1% in May, exceeding expectations. The iShares MSCI Germany ETF is gaining, supported by strong performances from key holdings.

30 jun 2026, 20:02 UTC

Correlated Moves
Social Media
News

Applied Materials shares are higher today following price target increases, including Susquehanna's raise to $900 from $575, reflecting strong analyst sentiment.

30 jun 2026, 20:01 UTC

News

Expedia Group Inc shares are lower today amid a decline in the Hotels, Resorts & Cruise Lines sector. Wells Fargo cut its price target to $303.

30 jun 2026, 20:01 UTC

News

ASML Holding NV shares are higher amid positive sentiment and Bernstein's price target increase, supported by $518 billion in semiconductor infrastructure investments.

30 jun 2026, 20:01 UTC

News
Correlated Moves

Intuitive Surgical shares are lower, reaching a four-week low amid declines in the Health Care Equipment sub-sector and volatility in the market.

30 jun 2026, 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

30 jun 2026, 19:56 UTC

News

Henry Schein announced a partnership with GoTu Technology to enhance dental workforce support, though shares are lower during Tuesday's session.

30 jun 2026, 19:56 UTC

News
Correlated Moves

Concerns over currency volatility arise as the yen weakens against the dollar. EUR/HKD remains roughly flat since Monday's close amid broader market dynamics.

30 jun 2026, 19:52 UTC

News

Costco Wholesale shares are lower, reaching a four-week low of $938.50, amid declines in the Consumer Staples Merchandise Retail sub-sector.

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

4.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 81 USD  4.95%

Hoogste 96 USD

Laagste 57 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

2

Hold

1

Sell

Sentiment

By Acuity

123 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat